C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Andrew Hirsch, the company's president and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 2:15 PM PST (5:15 PM EST).
The presentation will be accessible via live webcast through C4T's website in the Events & Presentations section. Interested parties who cannot attend the live session can access a replay of the webcast, which will remain available on the company's website for a minimum of two weeks following the presentation.
C4 Therapeutics (Nasdaq: CCCC), un'azienda biofarmaceutica in fase clinica focalizzata sulla scienza della degradazione mirata delle proteine, ha annunciato la propria partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Andrew Hirsch, presidente e CEO dell'azienda, terrà una presentazione mercoledì, 15 gennaio 2025, alle 14:15 PST (17:15 EST).
La presentazione sarà accessibile tramite webcast dal vivo attraverso il sito web di C4T nella sezione Eventi e Presentazioni. Le parti interessate che non possono partecipare alla sessione dal vivo possono accedere a una registrazione del webcast, che rimarrà disponibile sul sito dell'azienda per un minimo di due settimane dopo la presentazione.
C4 Therapeutics (Nasdaq: CCCC), una empresa biofarmacéutica en etapa clínica centrada en la ciencia de la degradación de proteínas dirigida, ha anunciado su participación en la 43.ª Conferencia Anual de Cuidado de la Salud de J.P. Morgan. Andrew Hirsch, presidente y CEO de la empresa, ofrecerá una presentación el miércoles 15 de enero de 2025, a las 2:15 PM PST (5:15 PM EST).
La presentación estará accesible a través de una transmisión web en vivo a través del sitio web de C4T en la sección de Eventos y Presentaciones. Las partes interesadas que no puedan asistir a la sesión en vivo pueden acceder a una repetición de la transmisión, que permanecerá disponible en el sitio web de la empresa durante un mínimo de dos semanas después de la presentación.
C4 Therapeutics (Nasdaq: CCCC)는 표적 단백질 분해 과학에 중점을 둔 임상 단계의 생물 제약 회사로, 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 앤드류 허시는 회사의 사장 겸 CEO로, 2025년 1월 15일 수요일 오후 2시 15분 PST (오후 5시 15분 EST)에 발표를 진행할 예정입니다.
발표는 C4T 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 라이브 웹캐스트로 접속할 수 있습니다. 실시간 세션에 참석할 수 없는 관심 있는 분들은, 발표 후 최소 2주 동안 회사 웹사이트에서 제공될 웹캐스트 재생을 통해 접근할 수 있습니다.
C4 Therapeutics (Nasdaq: CCCC), une entreprise biopharmaceutique en phase clinique axée sur la science de la dégradation ciblée des protéines, a annoncé sa participation à la 43e Conférence Annuelle de J.P. Morgan Healthcare. Andrew Hirsch, le président et PDG de l'entreprise, fera une présentation le mercredi 15 janvier 2025, à 14h15 PST (17h15 EST).
La présentation sera accessible via un webcast en direct sur le site Web de C4T dans la section Événements et Présentations. Les parties intéressées qui ne peuvent pas assister à la session en direct pourront accéder à un replay du webcast, qui restera disponible sur le site de l'entreprise pendant au moins deux semaines après la présentation.
C4 Therapeutics (Nasdaq: CCCC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Wissenschaft der gezielten Proteinabbau konzentriert, hat seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare angekündigt. Andrew Hirsch, der Präsident und CEO des Unternehmens, wird am Mittwoch, den 15. Januar 2025, um 14:15 Uhr PST (17:15 Uhr EST) eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast auf der Website von C4T im Abschnitt Veranstaltungen & Präsentationen zugänglich sein. Interessierte, die nicht an der Live-Sitzung teilnehmen können, haben die Möglichkeit, eine Aufzeichnung des Webcasts abzurufen, die mindestens zwei Wochen nach der Präsentation auf der Unternehmenswebsite verfügbar bleibt.
- None.
- None.
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president and chief executive officer of C4T, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST).
The presentation will be webcast live and may be accessed through C4T’s website on the Events & Presentations page. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
When is C4 Therapeutics (CCCC) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch C4 Therapeutics' (CCCC) J.P. Morgan Healthcare Conference presentation?
How long will C4 Therapeutics' (CCCC) J.P. Morgan presentation replay be available?
Who is presenting for C4 Therapeutics (CCCC) at the 2025 J.P. Morgan Healthcare Conference?
